Searchable abstracts of presentations at key conferences in endocrinology

ea0092op-02-03 | Oral Session 2: Thyroid hormone action in the brain | ETA2023

Effects of maternal administration of TH-Analog sobetirome and its CNS-Selective prodrug SOB-AM2 in murine MCT8-deficient fetuses

Valcarcel-Hernandez Victor , Guillen Yunta Marina , Scanlan Thomas S. , Barez-Lopez Soledad , Guadano-Ferraz Ana

Inactivating mutations in the thyroid hormones (TH) transporter monocarboxylate transporter 8 (MCT8) lead to the X-linked rare disease named MCT8 deficiency or Allan-Herndon-Dudley Syndrome (AHDS). AHDS pathophysiology is characterized by peripheral hyperthyroidism and cerebral hypothyroidism, which results in severe neurological impairments. Although AHDS leads to a spectrum of severe endocrine and neurological alterations, treatment options for MCT8-deficient patients are li...

ea0014oc10.6 | Obesity & metabolism | ECE2007

3-Iodothyronamine (T1AM) is a novel modulator of metabolic rate and glucose homeostasis

Grandy David K. , Suchland Katherine L. , Keck Thomas M. , Yan Feifei , Shyng Show-Ling , Scanlan Thomas S.

3-Iodothyronamine (T1AM) is a novel endogenous derivative of thyroid hormone (TH), recently described by Scanlan et al. (Nat. Med. 10: 638, 2004). In vitro, T1AM can stimulate the production of cAMP via activation of a heterologously expressed G protein-coupled receptor (GPCR) now referred to as trace amine-associated receptor 1 (TAAR1; Lindemann et al. Genomics 85: 372, 2005). In adult, unanesthetized C57Bl6/J mice, T1AM produces prof...